JP2016505613A - Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物 - Google Patents

Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物 Download PDF

Info

Publication number
JP2016505613A
JP2016505613A JP2015551250A JP2015551250A JP2016505613A JP 2016505613 A JP2016505613 A JP 2016505613A JP 2015551250 A JP2015551250 A JP 2015551250A JP 2015551250 A JP2015551250 A JP 2015551250A JP 2016505613 A JP2016505613 A JP 2016505613A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
months
oil
mcg
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015551250A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016505613A5 (enExample
Inventor
キドロン，ミリアム
アービット，エフド
Original Assignee
オラムド エルティーディー．
オラムド エルティーディー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IL2013/050007 external-priority patent/WO2013102899A1/en
Application filed by オラムド エルティーディー．, オラムド エルティーディー． filed Critical オラムド エルティーディー．
Publication of JP2016505613A publication Critical patent/JP2016505613A/ja
Publication of JP2016505613A5 publication Critical patent/JP2016505613A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/56—Protease inhibitors from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2015551250A 2013-01-03 2014-01-02 Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物 Pending JP2016505613A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/IL2013/050007 WO2013102899A1 (en) 2012-01-03 2013-01-03 Methods and compositions for treating diabetes
ILPCT/IL2013/050007 2013-01-03
US201361763996P 2013-02-13 2013-02-13
US61/763,996 2013-02-13
PCT/IL2014/050007 WO2014106846A2 (en) 2013-01-03 2014-01-02 Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018131875A Division JP2018197240A (ja) 2013-01-03 2018-07-11 Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物

Publications (2)

Publication Number Publication Date
JP2016505613A true JP2016505613A (ja) 2016-02-25
JP2016505613A5 JP2016505613A5 (enExample) 2017-01-05

Family

ID=51062529

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015551250A Pending JP2016505613A (ja) 2013-01-03 2014-01-02 Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物
JP2018131875A Pending JP2018197240A (ja) 2013-01-03 2018-07-11 Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物
JP2020102461A Pending JP2020180126A (ja) 2013-01-03 2020-06-12 Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物
JP2022156787A Pending JP2023002570A (ja) 2013-01-03 2022-09-29 Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物
JP2025040577A Pending JP2025106279A (ja) 2013-01-03 2025-03-13 Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018131875A Pending JP2018197240A (ja) 2013-01-03 2018-07-11 Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物
JP2020102461A Pending JP2020180126A (ja) 2013-01-03 2020-06-12 Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物
JP2022156787A Pending JP2023002570A (ja) 2013-01-03 2022-09-29 Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物
JP2025040577A Pending JP2025106279A (ja) 2013-01-03 2025-03-13 Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物

Country Status (5)

Country Link
US (4) US20150335715A1 (enExample)
EP (2) EP4215205A1 (enExample)
JP (5) JP2016505613A (enExample)
CN (2) CN104902921A (enExample)
WO (1) WO2014106846A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019529566A (ja) * 2016-09-28 2019-10-17 アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 非アルコール性脂肪性肝炎の治療のための方法及び医薬組成物

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2621577C (en) * 2005-09-06 2013-12-24 Oramed Pharmaceuticals, Inc. Methods and compositions for oral administration of proteins
JP5395160B2 (ja) 2008-03-26 2014-01-22 オラムド エルティーディー． タンパク質の経口投与方法及び組成物
JP2011519915A (ja) 2008-05-05 2011-07-14 オラムド エルティーディー． エクセナチドの経口投与用の方法および組成物
ES2644962T3 (es) 2012-01-03 2017-12-01 Oramed Ltd. Cápsulas que contiene composiciones líquidas basadas en aceite de agentes terapéuticos combinados para tratar la diabetes
HUE066433T2 (hu) 2012-02-01 2024-08-28 Oramed Ltd Proteáz inhibitort tartalmazó készítmények, azokat tartalmazó összetevõk, valamint eljárások azok elõállítására és felhasználására
EP4215205A1 (en) 2013-01-03 2023-07-26 Oramed Ltd. Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof
EP2975023B1 (en) 2013-03-13 2018-05-30 Takeda Pharmaceutical Company Limited Guanidinobenzoic acid ester compound
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
US10980866B2 (en) * 2014-09-22 2021-04-20 Hadasit Medical Research Services And Development Ltd. Alpha-1 anti-trypsin for treating liver diseases
CN109806386A (zh) * 2017-11-20 2019-05-28 江苏恒瑞医药股份有限公司 Fxr激动剂与glp-1类似物的药物组合物和用途
US20210244806A1 (en) * 2018-06-11 2021-08-12 Oramed Ltd. Recombinant Protease Inhibitor-Containing Compositions, Methods for Producing Same and Uses Thereof
WO2021142733A1 (en) * 2020-01-16 2021-07-22 Shanghai Benemae Pharmaceutical Corporation Combinational therapy comprising glp-1 and/or glp-1 analogs, and insulin and/or insulin analogs
CN116251192A (zh) * 2020-01-16 2023-06-13 上海仁会生物制药股份有限公司 Glp-1给药方案

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006238886A (ja) * 1992-11-17 2006-09-14 E I Du Pont De Nemours & Co 変化したレベルの不飽和脂肪酸を含有する種子油およびその生産方法
JP2011515458A (ja) * 2008-03-26 2011-05-19 オラムド エルティーディー． タンパク質の経口投与方法及び組成物
JP2011519915A (ja) * 2008-05-05 2011-07-14 オラムド エルティーディー． エクセナチドの経口投与用の方法および組成物

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68769A (en) 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
JPS6350793A (ja) 1986-08-20 1988-03-03 株式会社東芝 高速増殖炉の崩壊熱除去システム
US5034415A (en) 1987-08-07 1991-07-23 Century Laboratories, Inc. Treatment of diabetes mellitus
ES2045276T3 (es) 1988-07-21 1994-01-16 Hoffmann La Roche Preparacion de insulina
JPH02250823A (ja) 1989-03-24 1990-10-08 Tsumura & Co マイクロカプセル剤およびその製造方法
GB9007052D0 (en) 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
US5206219A (en) 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
US6692766B1 (en) 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
IL114673A (en) 1995-07-19 2000-12-06 Hadasit Med Res Service Pharmaceutical compositions containing protein for oral administration
JPH09208485A (ja) 1996-01-31 1997-08-12 Teijin Ltd ペプチド・蛋白質性薬物の水難溶性組成物
JP2001501593A (ja) 1996-08-08 2001-02-06 アミリン・ファーマシューティカルズ，インコーポレイテッド 胃腸運動を調節するための方法
JPH10330287A (ja) 1997-03-31 1998-12-15 Nippon Suisan Kaisha Ltd 多価不飽和脂肪酸からなる消化管吸収促進剤およびそれを含有する薬剤
JP2000128805A (ja) 1998-10-27 2000-05-09 Nippon Suisan Kaisha Ltd 多価不飽和脂肪酸および高分子ゲルからなる経粘膜吸収促進剤及びそれを含有する薬剤
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
CN100389821C (zh) * 1999-10-04 2008-05-28 希龙公司 稳定化的含多肽的液体药物组合物
JP2001240558A (ja) 2000-02-29 2001-09-04 Nippon Suisan Kaisha Ltd 多価不飽和脂肪酸を経粘膜吸収促進剤として含有する固形製剤。
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
KR20010069322A (ko) 2001-03-08 2001-07-25 서종수 휴대형정보단말기 또는 화상이동통신장치를 이용한전자경매방법
KR20010069433A (ko) 2001-03-22 2001-07-25 김윤완 노루궁뎅이버섯을 이용한 건강 보조 식품
CN1160122C (zh) 2001-04-20 2004-08-04 清华大学 一种制备口服胰岛素油相制剂的方法
AU2002316717B8 (en) 2001-07-18 2005-09-29 Solae Holdings Llc High protein, Bowman-Birk Inhibitor Concentrate and process for its manufacture
US20030198666A1 (en) 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
US20050143303A1 (en) 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
US20050232981A1 (en) 2004-04-15 2005-10-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
WO2006014673A2 (en) 2004-07-19 2006-02-09 Nobex Corporation Insulin-oligomer conjugates, formulations and uses thereof
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
EP1789075A4 (en) 2004-08-25 2009-07-01 Uab Research Foundation ABSORPTION ENHANCER FOR DRUG ADMINISTRATION
ES2325773T5 (es) * 2004-11-01 2014-02-24 Amylin Pharmaceuticals, Llc. Tratamiento de la obesidad y de los trastornos relacionados
WO2007022518A2 (en) * 2005-08-19 2007-02-22 Amylin Pharmaceuticals, Inc. New uses of glucoregulatory proteins
CA2621577C (en) * 2005-09-06 2013-12-24 Oramed Pharmaceuticals, Inc. Methods and compositions for oral administration of proteins
US20070086972A1 (en) 2005-09-12 2007-04-19 Jacob Birnbaum Hair growth compositions and methods for treating hair loss or related conditions
US20070077283A1 (en) 2005-09-30 2007-04-05 Nastech Pharmaceutical Company Inc. Method of enhancing transmucosal delivery of therapeutic compounds
CN101095942B (zh) 2006-06-30 2011-11-16 北京民海生物科技有限公司 一种包含稳定剂的Exendin-4注射剂药物配方
RU2509071C2 (ru) 2006-11-01 2014-03-10 Пронова Биофарма Норге Ас Новые липидные соединения
WO2008117062A1 (en) 2007-03-28 2008-10-02 Aker Biomarine Asa Bioeffective krill oil compositions
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
JPWO2009151125A1 (ja) * 2008-06-13 2011-11-17 持田製薬株式会社 肝障害の診断及び治療
JPWO2009154230A1 (ja) 2008-06-17 2011-12-01 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
EA020326B9 (ru) * 2008-06-17 2015-03-31 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Агонисты смешанного действия на основе глюкозозависимого инсулинотропного пептида для лечения нарушений обмена веществ и ожирения
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
JP2011526888A (ja) 2008-07-01 2011-10-20 ザ・ジョンズ・ホプキンス・ユニバーシティ 治療薬を標的送達するための経口速溶性薄膜
RU2494755C2 (ru) 2008-08-18 2013-10-10 Интера Био Лтд. Способы и композиции для перорального введения белков
UY32177A (es) 2008-10-16 2010-05-31 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético
PL2427415T3 (pl) 2009-05-08 2019-09-30 Basf As Wielonienasycone kwasy tłuszczowe do leczenia chorób związanych z dziedziną chorób sercowo-naczyniowych, metabolicznych i zapalnych
EP2488180A4 (en) 2009-10-12 2013-03-27 Ipca Lab Ltd PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT / PROPHYLAXIS OF NON ALCOHOLIC HEPATIC STEATOSIS
WO2011082360A1 (en) 2009-12-30 2011-07-07 Solae, Llc Method for recovering kunitz-trypsin inhibitor proteins from a soy processing stream
US20130273154A1 (en) 2011-03-02 2013-10-17 Joseph M. Fayad Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes
KR20230051307A (ko) * 2010-06-24 2023-04-17 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
CN102970981A (zh) * 2010-07-06 2013-03-13 詹森药业有限公司 糖尿病协同治疗制剂
EP2675275B1 (en) * 2011-02-14 2017-12-20 The Regents Of The University Of Michigan Compositions and methods for the treatment of obesity and related disorders
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
CN102219850A (zh) * 2011-05-03 2011-10-19 上海格尼生物技术有限公司 新的长效glp-1化合物
EP2723359A4 (en) * 2011-06-24 2015-03-11 Amylin Pharmaceuticals Llc METHOD FOR THE TREATMENT OF DIABETES WITH THE HELP OF DELAYED RELEASED FORMULATIONS FROM GLP-1 RECEPTOR AGONISTS
WO2013010289A1 (zh) 2011-07-15 2013-01-24 Chan Tu Cheng 填充式工件表面饰化方法
US9458214B2 (en) * 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
ES2644962T3 (es) * 2012-01-03 2017-12-01 Oramed Ltd. Cápsulas que contiene composiciones líquidas basadas en aceite de agentes terapéuticos combinados para tratar la diabetes
HUE066433T2 (hu) 2012-02-01 2024-08-28 Oramed Ltd Proteáz inhibitort tartalmazó készítmények, azokat tartalmazó összetevõk, valamint eljárások azok elõállítására és felhasználására
US20150133373A1 (en) * 2012-03-28 2015-05-14 Amylin Pharmaceuticals, Llc Transmucosal delivery of engineered polypeptides
EP4215205A1 (en) * 2013-01-03 2023-07-26 Oramed Ltd. Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006238886A (ja) * 1992-11-17 2006-09-14 E I Du Pont De Nemours & Co 変化したレベルの不飽和脂肪酸を含有する種子油およびその生産方法
JP2011515458A (ja) * 2008-03-26 2011-05-19 オラムド エルティーディー． タンパク質の経口投与方法及び組成物
JP2011519915A (ja) * 2008-05-05 2011-07-14 オラムド エルティーディー． エクセナチドの経口投与用の方法および組成物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AMERICAN JOURNAL OF PHYSIOLOGY ENDOCRINOLOGY AND METABOLISM, vol. 292, no. 3, JPN6018040512, 1 March 2007 (2007-03-01), pages 829 - 835, ISSN: 0003899288 *
MMR IN BIOMEDICINE, vol. 24, no. 7, JPN6018040514, August 2011 (2011-08-01), pages 784 - 790, ISSN: 0003899290 *
PLOS ONE[オンライン], vol. Volume 6, Issue 9, JPN6017033126, 11 September 2011 (2011-09-11), ISSN: 0003899286 *
日本内科学会雑誌, vol. 第１０１巻 第３号, JPN6018040513, 10 March 2012 (2012-03-10), pages 662 - 668, ISSN: 0003899289 *
日本栄養・食糧学会誌, vol. 第６４巻, 第２号, JPN6017033129, 2011, pages 91 - 98, ISSN: 0003899287 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019529566A (ja) * 2016-09-28 2019-10-17 アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 非アルコール性脂肪性肝炎の治療のための方法及び医薬組成物
JP7022136B2 (ja) 2016-09-28 2022-02-17 アイガー・バイオファーマシューティカルズ・インコーポレイテッド 非アルコール性脂肪性肝炎の治療のための方法及び医薬組成物
US11571403B2 (en) 2016-09-28 2023-02-07 Eiger Biopharmaceuticals, Inc. Methods for the treatment of non-alcoholic steatohepatitis

Also Published As

Publication number Publication date
CN104902921A (zh) 2015-09-09
WO2014106846A3 (en) 2015-01-29
EP4215205A1 (en) 2023-07-26
JP2025106279A (ja) 2025-07-15
US20190209655A1 (en) 2019-07-11
US20240181018A1 (en) 2024-06-06
JP2018197240A (ja) 2018-12-13
EP2941267A2 (en) 2015-11-11
EP2941267B1 (en) 2022-11-16
EP2941267A4 (en) 2016-06-22
HK1217291A1 (en) 2017-01-06
CN110151979A (zh) 2019-08-23
JP2023002570A (ja) 2023-01-10
WO2014106846A2 (en) 2014-07-10
US20150335715A1 (en) 2015-11-26
JP2020180126A (ja) 2020-11-05
US10967051B2 (en) 2021-04-06
US20220000986A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
US10967051B2 (en) Methods and compositions for treating NAFLD, hepatic steatosis, and sequelae thereof
US20230210956A1 (en) Methods and compositions for treating diabetes
RU2494755C2 (ru) Способы и композиции для перорального введения белков
ES2670856T3 (es) Métodos y composiciones para la administración oral de proteínas
KR20150127599A (ko) 비알코올성 지방간염을 치료하기 위한 조성물 및 방법
US20250387453A1 (en) Methods and Compositions for Treating Diabetes
HK1217291B (en) Compositions for use in treating nafld
AU2015243030B2 (en) Methods and compositions for oral administration of proteins
HK1203826B (en) Capsules containing oil-based liquid compositions of combined therapeutic agents for treating diabetes
AU2014218446B2 (en) Methods and compositions for oral administration of proteins
HK1158938A (en) Methods and compositions for oral administration of proteins
HK1158938B (en) Methods and compositions for oral administration of proteins
IL189956A (en) Compositions for oral administration of proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180131

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180711

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180820

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20181019

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190515